Physician profile
Sean Goddard
NPI 1285117143
$179,652.05
in general payments reported to CMS, 2019-2025
17 companies · $128K in 2025
The $128K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $3,345 · 2023: $1,064 · 2024: $47K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $93K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $23K · Consulting Fee: $21K · Food and Beverage: $8,899 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $93,371.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,135.00 |
| Travel and Lodging | $23,147.83 |
| Consulting Fee | $21,365.00 |
| Food and Beverage | $8,899.49 |
| Education | $130.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $139,337.07 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $35,438.61 | 2022-2025 | Spravato |
| Brainsway USA INC | $3,086.00 | 2021-2022 | |
| Abbvie INC. | $448.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.24 | 2021-2025 | Trintellix |
| Noven Therapeutics, LLC | $238.33 | 2023-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $233.36 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $125.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $62.02 | 2022-2023 | Qelbree |
| Corium, LLC | $61.99 | 2022-2023 | Azstarys |
| Acadia Pharmaceuticals INC | $33.84 | 2021-2023 | Nuplazid |
| Collegium Pharmaceutical, INC. | $28.06 | 2025 | Jornay Pm |
| Neuronetics, INC. | $26.33 | 2024 | Neurostar Tms Therapy System |
| Sun Pharmaceutical Industries INC. | $19.33 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14.60 | 2021 | |
| Indivior INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Goddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.